How brain-derived exosomes relate to Alzheimer's disease and cognitive decline after traumatic brain injury.
Official title: Impact of TBI and Cognitive Decline on Alzheimer's Disease Brain-Derived Exosome Cargo
Funded at University of Southern California · NIH-10662883 · Data updated 2026-11-12
This study is looking at tiny particles in the blood that come from the brain to see how they might help us understand Alzheimer's disease, especially in people who have had a head injury, and it hopes to find clues that could help track how the disease progresses in older adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project start | June 1, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $1,948,168 |
| NIH project number | 1RF1AG079303-01A1 |
| Project ID | NIH-10662883 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults who have experienced traumatic brain injury and are showing signs of cognitive decline.
✕Less likely to help
Patients who do not have a history of traumatic brain injury or those who are not experiencing cognitive decline may not benefit from this research.
What this research studies
This research investigates the role of brain-derived exosomes in Alzheimer's disease, particularly focusing on how traumatic brain injury (TBI) may influence cognitive decline. By analyzing exosomes from plasma, which carry specific proteins related to brain health, the study aims to identify biomarkers that could indicate the progression of Alzheimer's disease. The research utilizes existing plasma samples to explore the connection between exosome protein content and cognitive changes in older adults, providing insights into potential diagnostic tools for Alzheimer's.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic methods for Alzheimer's disease, allowing for earlier detection and better management of the condition.
How similar studies have gone: Previous research has shown promise in using exosome biomarkers for neurodegenerative diseases, indicating that this approach may yield valuable insights.
Where this research is happening
-
University of Southern California
Los Angeles, United States Active
Researchers
- Principal investigator: Rissman, Robert — University of Southern California
- Study coordinator: Rissman, Robert
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
NGF Metabolism as a biomarker for cognitive decline in familial Alzheimer's disease
Researchers are studying whether patterns in nerve growth factor pathways in blood and CSF can signal early, preclinical stages of Alzheimer's in people with genetic risk.
-
NGF metabolism as an early biomarker for cognitive decline in familial Alzheimer's disease
This project tests whether NGF pathway proteins in blood and CSF can signal early, preclinical changes in people with familial Alzheimer’s disease.
-
NGF Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's Disease
This project looks at nerve growth factor pathways in people with a genetic form of Alzheimer's to see if blood and spinal fluid markers can identify early brain changes before symptoms appear.
-
Remote monitoring of Alzheimer’s changes in adults with Down syndrome
A study tests remote (at-home) ways to track Alzheimer’s-related thinking changes in adults with Down syndrome.
-
Tumor Susceptibility Gene 101: a microglial therapy approach to protect memory in Alzheimer’s disease
A Mayo Clinic team is studying a protein called TSG101 in brain immune cells to slow or prevent cognitive decline in Alzheimer’s disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.